Latest news : Gamida Cell Ltd.

27/25/27	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/24/22	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/24/18	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/24/18	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/24/18	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
18/24/18	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
24/24/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/24/10	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
05/24/05	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
28/24/28	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/24/28	Top Premarket Decliners	MT
27/24/27	Top Midday Decliners	MT
27/24/27	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

More news

Analysts' recommendations : Gamida Cell Ltd.

30/24/30	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
15/23/15	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/23/15	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/23/19	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/23/16	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases : Gamida Cell Ltd.

27/24/27	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/24/27	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/24/22	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
23/24/23	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/24/29	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors : Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	01/06/2021
Rory Nealon COO	Chief Operating Officer	59	24/05/2024

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	01/04/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets 10:24:51 24/05/2024 pm IST			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	26.18L 22.53L 21.2L 19.36L 36.22L 25Cr 36.32L 2.5Cr 97.2L 13Cr 98.32L 96.17L 41Cr	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	3.9Cr 3.36Cr 3.16Cr 2.88Cr 5.4Cr 368.29Cr 5.41Cr 37Cr 14Cr 188.96Cr 15Cr 14Cr 608.74Cr	EV / Sales 2022	-	EV / Sales 2023	5,10,81,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

3 years	0.01	1.26
5 years	0.01	4.72
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/01/24	Ronit Simantov	Free	Chief Technology Officer	4,80,319	0.3621%
31/01/24	Ivan Borrello	Free	Director	2,00,000	0.1508%
31/01/24	Kenneth Moch	Free	Director	2,00,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.63%	26.19L
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+50.90%	+89.03%	6.9TCr
ARGENX SE	-2.06%	-0.18%	+41.53%	+88.17%	6.63TCr
INSMED INCORPORATED	-0.31%	+6.54%	-11.39%	+457.82%	2.77TCr
BIONTECH SE	+0.86%	+1.65%	+0.25%	-14.78%	2.58TCr
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.90%	+39.40%	+9.41%	2.65TCr
GENMAB A/S	-1.46%	+0.42%	+24.07%	-18.70%	2.04TCr
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+210.71%	+370.84%	1.76TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-4.88%	-0.41%	+530.26%	1.51TCr
EXELIXIS, INC.	-0.20%	+8.37%	+57.87%	+159.50%	1.47TCr
Average	-1.00%	+0.05%	+41.29%	+157.29%	2.83TCr
Weighted average by Cap.	-1.53%	-0.34%	+42.56%	+144.94%

Gamida Cell Ltd. Share Price

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation : Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations : Gamida Cell Ltd.

Press Releases : Gamida Cell Ltd.

Quotes and Performance

Price Extremes

Managers and Directors : Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

	2022	2023
Net sales	-	1.78 1.54 1.44 1.32 2.47 168.44 2.47 17.07 6.62 86.42 6.7 6.55 278.41
Net income	-7.94Cr -6.83Cr -6.43Cr -5.87Cr -11Cr -749.43Cr -11Cr -76Cr -29Cr -384.51Cr -30Cr -29Cr -1.24TCr	-6.3Cr -5.42Cr -5.1Cr -4.66Cr -8.72Cr -594.78Cr -8.74Cr -60Cr -23Cr -305.16Cr -24Cr -23Cr -983.1Cr
Net Debt	3.93Cr 3.38Cr 3.18Cr 2.91Cr 5.44Cr 371.13Cr 5.45Cr 38Cr 15Cr 190.42Cr 15Cr 14Cr 613.43Cr	3.64Cr 3.13Cr 2.95Cr 2.69Cr 5.03Cr 343.57Cr 5.05Cr 35Cr 14Cr 176.27Cr 14Cr 13Cr 567.88Cr